Form 4: Protara Therapeutics CEO Transfers 300,000 Shares to Family Trust, Retains Beneficial Ownership

Jesse Shefferman, CEO and President of Protara Therapeutics, Inc., transferred 300,000 shares of common stock to The Samhold Family Trust, while explicitly retaining beneficial ownership.

Summary

• Jesse Shefferman, the CEO and President of Protara Therapeutics, Inc. (TARA), transferred 300,000 shares of the company's common stock.
• The transaction took place on June 24, 2025, and involved the transfer of shares to The Samhold Family Trust for no consideration.
• This transfer represents a change in the form of ownership for these 300,000 shares, moving them from direct to indirect beneficial ownership.
• Members of Mr. Shefferman's immediate family are the sole beneficiaries of The Samhold Family Trust, and a family member serves as a trustee.
• Mr. Shefferman explicitly stated that he remains the beneficial owner of the 300,000 shares held by the trust.
• Following this transaction, Mr. Shefferman directly owns 659,886 shares and indirectly owns 300,000 shares through The Samhold Family Trust, resulting in a total beneficial ownership of 959,886 shares.

Sentiment

Score: 5

Explanation: The transfer of shares to a family trust, while retaining beneficial ownership, is a neutral event from an operational or financial performance perspective. It primarily reflects personal estate planning by the CEO and does not indicate a change in company fundamentals.

Positives

• CEO Jesse Shefferman maintains beneficial ownership of the 300,000 shares transferred to The Samhold Family Trust, indicating continued alignment with shareholder interests and long-term commitment to the company.

Negatives

• No direct negative financial or operational impacts are indicated by this change in beneficial ownership form.

Risks

• No specific risks are identified in this filing, as it primarily reports a change in the form of beneficial ownership rather than operational or financial risks.

Future Outlook

No forward-looking statements or guidance regarding the company's future performance or strategic direction are provided in this beneficial ownership report.

Management Comments

• "On June 24, 2025, the reporting person transferred 300,000 shares of common stock to The Samhold Family Trust for no consideration."
• "Members of the reporting person's immediate family are the sole beneficiaries of the trust and a member of the reporting person's immediate family serves as a trustee thereof."
• "The reporting person remains the beneficial owner of the securities held by the trust."

Industry Context

This filing is a routine insider transaction report specific to an individual's beneficial ownership and does not provide information relevant to broader industry trends or competitive analysis within the biotechnology or pharmaceutical sector.

Comparison to Industry Standards

• Not applicable, as this document reports an individual's beneficial ownership change rather than company performance metrics or operational results that could be benchmarked against industry standards or comparable companies.

Management Changes

Corporate Governance

Legal Proceedings

• No litigation or regulatory matters are disclosed in this filing.

Related Party Transactions

• The transfer of 300,000 shares to The Samhold Family Trust, whose beneficiaries are members of the reporting person's immediate family, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The CEO's continued beneficial ownership of the transferred shares may be viewed as a sign of long-term commitment to the company.
• Employees, customers, suppliers, and creditors: No direct impact on these stakeholders is indicated by this filing, as it pertains to an individual's personal shareholdings.

Next Steps

• No specific future actions, events, or milestones for the company are detailed in this beneficial ownership report.

Key Dates

Keywords

Protara Therapeutics, TARA, Jesse Shefferman, Form 4, beneficial ownership, stock transfer, family trust, CEO, insider transaction